Calls for papers
-
According to Aradigm, the first patient in the Phase 3 ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial of Pulmaquin inhaled ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis has been dosed. The other Phase 3… Read more . . .
-
Verona Pharma has announced that it will stop development of its VRP700 inhaled antitussive after the drug failed to produce statistically significant reduction in cough frequency compared to placebo in a Phase 2a clinical trial.… Read more . . .
-
Under the terms of a newly reached settlement, Perrigo and Catalent will be able to market limited quantities of their generic version of Teva’s Proair HFA albuterol MDI starting in December 2016. Beginning in July… Read more . . .
-
Asmacure has announced that a Phase 1/2a trial of ASM-024 inhalation powder found that the drug was safe and well tolerated. In April 2013, the company announced that it had dosed the first patient in… Read more . . .
-
According to Consort Medical’s financial report for the fiscal year ending April 2014, its Bespak subsidiary is adding a 4,200 sq m facility for the manufacture of a nicotine DPI and a 5,200 sq m… Read more . . .
-
Discovery Laboratories says that it will use the $1.9 million it has received from the National Heart, Lung, and Blood Institute (NHLBI) for a Phase 2a trial of Aerosurf inhaled KL4 surfactant that is already… Read more . . .
-
GlaxoSmithKline and Theravance have announced that two Phase 3 studies have shown that COPD patients using the Incruse Ellipta umeclidinium (UMEC) DPI in conjunction with the Breo/Relvar Ellipta fluticasone furoate/vilanterol (FF/VI) DPI achieved a statistically… Read more . . .
-
AstraZeneca has paid $7.25 million up-front with potential milestone payments of up to $225 million for a global licence from Synairgen for its SNG001 inhaled interferon beta for the treatment of viral respiratory tract infections… Read more . . .
-
OptiNose has announced three hires for senior management positions, which it says “will help drive the company forward in its mission to introduce new and valuable treatment options to the market utilizing its novel Bi-Directional… Read more . . .
-
Strativa Pharmaceuticals has announced that it has received FDA approval for its disposable single-dose device version of Nascobal cyanocobalamin nasal spray for the treatment of pernicious anemia and other vitamin B12 deficiencies. The new product… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan